Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…esectable CSCC. Neoadjuvant ICIs studies, including cemiplimab, pembrolizumab, and nivolumab±ipilimumab, have reported consistent and strikin…
…Background Nivolumab plus ipilimumab (COMBO) is the standard treatment for asymptoma…
…cts. We describe a complex case of NT1 following ipilimumab and nivolumab exposure for management of metastatic melanoma.…
…Results In 2023 and 2024 we used seven immunotherapeutic drugs: pembrolizumab (230 patients), durvalumab (45 patients), atezolizumab (45 pati…
…gical therapy (21%), and other (9%). Most implicated drugs were nivolumab, ipilimumab, carboplatin, paclitaxel, oxaliplatin, and pembroli…
…s with rare cancers treated with dual checkpoint blockade using ipilimumab plus nivolumab, based on data from 52 baskets in the DART SWOG …
… 70s with metastatic melanoma being treated with ipilimumab and nivolumab. He presented with febrile neutropenia after lacerating a thumb…
…umab (360 mg intravenously every 3 weeks) and cohort B received hydroxychloroquine (600 mg orally two times a day). The primary endpoint was safet…
…een 1L and second-line (2L) therapies) was twice as long versus sunitinib. TFS and survival states for ICI plus vascular endothelial grow…
…dence base is compatible with a favourable effect of first-line nivolumab plus ipilimumab for adults with untreated metastatic BRAF-mutan…
…TEZO, atezolizumab; BINI, binimetinib; COBI, cobimetinib; ENCO, encorafenib; ESS, effective sample size; DAB, dabrafenib; NIVO, nivolumab; …
…emotherapy, pembrolizumab-based chemoimmunotherapy (Pembro) and nivolumab plus ipilimumab with or without two cycles of platinum-doublet …